BioRestorative Therapies (BRTX) AI Stock Analysis

• Market Cap: $11.03M
• Dividend Yield: N/A
• Average Volume (3M): 90.22K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.11
• Revenue Growth: 175.03%
• EPS Growth: 55.34%
• Country: US
• Employees: 11
• Sector: Healthcare
• Sector Strength: 37
• Industry: Biotechnology
• EPS (TTM): -0.64
• Shares Outstanding: 7,504,780
• 10 Day Avg. Volume: 103,248
• 30 Day Avg. Volume: 90,215
• PEG Ratio: 0.04
• Price to Book (P/B): 2.02
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.27
• Enterprise Value/Market Cap: 0.94
• Enterprise Value/Revenue: 7.69
• Enterprise Value/Gross Profit: 28.69
• Enterprise Value/Ebitda: -0.22
• 1Y Price Target: $13.00
• Price Target Upside: 784.35% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 48 Neutral
• Price Target: ―

BioRestorative Therapies faces significant financial challenges with ongoing net losses and negative cash flow, affecting its stock performance. However, recent improvements in financial metrics, substantial revenue growth, and promising clinical developments provide some optimism. Technical indicators suggest a neutral market position. Although valuation remains a concern due to the lack of profitability, the company's strategic focus on clinical trials and research offers potential for future growth.

Positive Factors

Clinical Trial Results

The blinded data continues to trend positively, with 74% of subjects demonstrating more than 50% improvement in function and 72% demonstrating more than 50% improvement in pain.

Regulatory Progress

BRTX-100 received Fast Track designation from the FDA, which could expedite the development process.

Negative Factors

Competitive Landscape

Increasing regulatory acceptance of MSCs is noted, with other companies making advancements in this space.

Financial Performance

The company reported a net loss of $4.8 million and revenue of $25,000.

BioRestorative Therapies Business Overview & Revenue Model

Company Description

BioRestorative Therapies (BRTX) is a biotechnology company focused on the development of innovative therapeutic solutions using cell and tissue therapies. The company operates primarily in the field of regenerative medicine, with a particular emphasis on stem cell-based therapies for the treatment of chronic lumbar disc disease and metabolic disorders. Its core products include BRTX-100, a stem cell-based therapeutic targeting disc/spine disease, and ThermoStem, a program focused on metabolic disorders including obesity and diabetes.

How the Company Makes Money

BioRestorative Therapies generates revenue through the development and commercialization of its proprietary cell and tissue-based therapeutic products. The company aims to earn revenue by advancing its clinical programs through various stages of regulatory approval, ultimately leading to product commercialization and sales. Key revenue streams include potential licensing agreements, strategic partnerships, and collaborations with pharmaceutical companies interested in its therapies. Additionally, BRTX may secure funding from grants and research subsidies as it progresses its clinical trials and expands its research initiatives. However, being a biotechnology company in the developmental stage, BioRestorative Therapies may also rely on equity financing and other forms of investment to support its operations until its therapies are fully developed and marketed.

BioRestorative Therapies Financial Statement Overview

Summary

BioRestorative Therapies is in a challenging financial position with consistent net losses and negative cash flows, despite some revenue growth. While the balance sheet shows reduced leverage and improved equity, the company's ability to generate cash and achieve profitability remains a significant concern. Continued focus on cost management and operational efficiency will be crucial for financial stability.

Income Statement

BioRestorative Therapies shows a significant increase in revenue year-over-year, but it remains small in absolute terms. Despite this, the company struggles with negative profitability metrics, including persistent net losses and negative EBIT and EBITDA margins, indicating ongoing operational challenges and high costs relative to revenue.

Balance Sheet

The company has improved its equity position with positive stockholders' equity, and it has no current total debt, reducing financial risk. However, the frequent large net losses impact the overall asset quality, and the equity ratio has been declining, signaling a need for better asset management.

Cash Flow

Operating cash flow has been consistently negative, reflecting ongoing cash outflows from operations. While free cash flow has seen slight improvement, it remains negative, indicating cash burn. The reliance on financing activities to support cash needs is evident, which may not be sustainable long-term without improved operational cash generation.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	401.00K	145.80K	119.80K	46.00K	77.00K
Gross Profit	372.93K	-19.93K	-160.87K	-159.21K	77.00K
EBITDA	-11.37M	-15.06M	-18.85M	-26.22M	-9.48M
Net Income	-8.98M	-10.42M	-18.02M	-29.94M	-12.25M
Balance Sheet
Total Assets	12.28M	12.61M	16.43M	22.45M	4.35M
Cash, Cash Equivalents and Short-Term Investments	10.73M	11.07M	14.75M	21.03M	3.06M
Total Debt	0.00	162.32K	301.64K	670.70K	4.79M
Total Liabilities	3.75M	2.61M	6.14M	856.50K	5.68M
Stockholders Equity	8.53M	10.00M	10.29M	21.60M	-1.33M
Cash Flow
Free Cash Flow	-8.34M	-6.60M	-6.31M	-3.36M	-1.96M
Operating Cash Flow	-8.23M	-6.43M	-5.87M	-3.33M	-1.96M
Investing Cash Flow	514.53K	3.25M	-13.48M	-30.66K	0.00
Financing Cash Flow	7.38M	2.35M	0.00	21.32M	5.03M

BioRestorative Therapies Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.47
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BRTX, the sentiment is Negative. The current price of 1.47 is below the 20-day moving average (MA) of 1.59, below the 50-day MA of 1.66, and below the 200-day MA of 1.72, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 38.40 is Neutral, neither overbought nor oversold. The STOCH value of 13.76 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BRTX.

BioRestorative Therapies Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.30B	0.27	-62.71%	2.44%	15.02%	0.60%
BRTX	48 Neutral	$11.03M	―	-117.16%	―	175.03%	55.34%
PHIO	42 Neutral	$11.42M	―	-76.12%	―	―	81.71%
IMNN	41 Neutral	$17.59M	―	-397.54%	―	―	24.16%
MEIP	41 Neutral	$33.65M	―	-89.73%	―	-100.00%	-292.59%
COCP	40 Underperform	$17.60M	―	-106.05%	―	―	9.46%
INAB	34 Underperform	$7.34M	―	-174.66%	―	―	38.53%

BioRestorative Therapies Corporate Events

BioRestorative Clarifies Recent Press Release Details

BioRestorative Therapies has released a statement clarifying that the information in their recent press release is being furnished and not filed, and will not be incorporated into any registration statement unless specifically identified. The company emphasizes that this does not constitute a determination or admission that the information is material or complete, nor should it be considered by investors for making investment decisions.

BioRestorative Therapies Issues Regulation FD Disclosure

The news release does not contain specific information about BioRestorative Therapies’ industry, primary products or services, or market focus. The release appears to reference a Current Report on Form 8-K without providing substantial details about the company’s operations or implications for stakeholders.